Auvelity becomes first non-antipsychotic approved for Alzheimer’s agitation
The approval of Auvelity was based on two Phase III trials: ADVANCE-1 (NCT03226522) and ACCORD-2 (NCT04797715).
Neurology
AAN 2026: New data demonstrates Symbravo’s cumulative benefit for acute migraine
AAN 2026: Solengepras demonstrates emerging benefit in early Parkinson’s disease
AAN 2026: BlueRock reports positive safety data for bemdaneprocel in Parkinson’s
AAN 2026: Phase I/II success for rese-cel in gMG signals potential amid competition
AAN 2026: new Vyvgart data show disease control in seronegative gMG
AAN 2026: frexalimab Phase II OLE data bolsters progressive MS ambitions
AAN 2026: Phase III success for azetukalner in focal epilepsy paves approval path
